Prime Medicine published Phase 1/2 clinical data for PM359 in NEJM, a one-time genetic therapy for CGD, presented at ASH.
Prime Medicine, Inc., a biotechnology company based in Cambridge, Massachusetts, disclosed crucial information on December 7, 2025. Their stock is listed as Nasdaq: PRME. They are known for their innovative genetic therapies that aim to provide a permanent cure. The company shared the results of Phase 1/2 clinical trials involving PM359. This particular product utilizes autologous hematopoietic stem cells and targets p47 phox chronic granulomatous disease (CGD). The findings were officially published in the prestigious New England Journal of Medicine (NEJM) and will be discussed in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, set to take place from December 6 to 9, 2025, in Orlando, Florida.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments